Join us in downtown Washington, DC next Saturday October 4th for the DC Lung Cancer Conference, an IASLC endorsed, 1-day CME meeting covering updates in lung cancer, featuring 58 thoughtful & dynamic faculty members. #DCLung25 Register today at medstarhealth.org/dclung25

What were the key highlights from #WCLC25 on Monday? In this #LungCancerConsidered episode, @narjustflorezmd.bsky.social & @stephenvliu.bsky.social discuss NADIM ADJUVANT, VATS vs lobectomy, and EA5181/LS SCLC results with leading experts. 🎧 bit.ly/WCLC25Mon

Can AI transform lung cancer care? In the newest episode of #LungCancerConsidered, @stephenvliu.bsky.social speaks with @arselaprelaj.bsky.social about how artificial intelligence is changing research, diagnostics & treatment in thoracic oncology. 🎧 bit.ly/AIandLCResea...

Join Discussion on Treating Rare Lung Cancer Subtypes at WCLC25 - Stephen V Liu @stephenvliu.bsky.social @solangepeters.bsky.social @mhennink.bsky.social oncodaily.com/voices/steph... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LungCancer #WCLC25

Learn what happens at September's World Conference for #LungCancer in Barcelona – no international travel needed! Our next Together Separately livestream will focus on news from this important meeting. Join us Thurs, Sept. 25 at 3:30 PM ET: LCRF.org/together @stephenvliu.bsky.social #WCLC25

A new ROS1+ NSCLC therapy is here. In the latest #LungCancerConsidered, @stephenvliu.bsky.social speaks with Dr. Enriqueta Felip & Dr. Jorge Nieva about the FDA approval of taletrectinib and how it fits into lung cancer care. 🎧 Tune in here: bit.ly/FDATaletrect... #IASLC #NSCLC

What’s the best approach to resectable EGFR-mutant NSCLC? In this #LungCancerConsidered Virtual Tumor Board, @stephenvliu.bsky.social leads a discussion with Drs. Chunxia Su & Collin Blakely exploring this complex clinical scenario. 🎧 bit.ly/VTBregfrnsclc #NSCLC #EGFR

What does the FDA approval of sunvozertinib mean for patients with EGFR exon 20 insertions? In this week’s #LungCancerConsidered, @stephenvliu.bsky.social talks with Dr. Mariam Alexander and Dr. James Chih-Hsin Yang about the newest EGFR-targeted therapy. 🎧 bit.ly/FDAexon20

Last chance! 🕐 Early bird registration for #WCLC25 ends today. Join us in Barcelona, Sept. 6–9, for the world’s leading conference on lung cancer. ✨ Discounted rates ✨ Global networking ✨ Cutting-edge research Register today → wclc.iaslc.org/registration/ #IASLC #LungCancer #OncologyConference

Herbert Loong presenting data on Sevabertinib in ERBB2/HER2 mutated NSCLC #ASCO25 Cohort with no prior treatment and another with no prior HER2 targeted therapy.

New Podcast: BTOG does … Tobacco Dependency in Lung Cancer. Dr Emma O’Dowd talks to Professor Sanjay Agrawal. Wherever you get your podcasts or listen online btog.org/btog-podcasts/ #LCSM #LungCancer

From HERTHENA-Lung02 to CheckMate 816, the latest #LungCancerConsidered episode breaks down major #ASCO25 lung cancer studies. Join @narjustflorezmd.bsky.social, @stephenvliu.bsky.social, @patrickforde.bsky.social and Dr. Charu Aggarwal for expert insights. 🎧 bit.ly/ASCO25LCC #NSCLC #SCLC

Join Dr. Noemi Reguart, Dr. Nicolas Girard, and me on Wednesday, June 25 at 9:30am EST (15:30 CEST) for this free webinar, where we will discuss the lung cancer highlights from #ASCO25. Global perspectives on emerging data! us06web.zoom.us/webinar/regi...

Proud to be part of the phase III IMforte team - the addition of maintenance lurbinectedin to standard maintenance atezolizumab for patients with #SCLC led to an improvement in PFS (HR 0.54) and an improvement in survival (OS HR 0.73), published in @thelancet.com. www.thelancet.com/journals/lan...

Congratulations to the newly elected SITC At-Large Directors - Drs. Tina Cascone, Aurelien Marabelle, and Ryan Sullivan! New SITC leadership joining an accomplished board in moving immunotherapy forward with the goal of long term survival for all of our patients! @sitcancer.bsky.social

Lots of lung cancer updates at #ASCO25. Listen to the latest episode of Lung Cancer Considered, the @iaslc.bsky.social podcast, for a discussion on highlights with Drs. @narjustflorezmd.bsky.social, Charu Aggarwal, @patrickforde.bsky.social and me. #LCSM www.iaslc.org/iaslc-news/l...

In the latest #LungCancerConsidered episode, @stephenvliu.bsky.social moderates a discussion featuring Dr. Mara Antonoff, Dr. Shankar Siva & Dr. David Carbone. They navigate a real-world case & explore current approaches to treatment & clinical decision-making. 🎧 Listen here: bit.ly/VTBresidual

The FDA has approved telisotuzumab vedotin for MET+ NSCLC! On this #LungCancerConsidered episode, @stephenvliu.bsky.social, Dr. Mor Moskovitz and Dr. Jonathan Goldman break down what this means for lung cancer care. 🎧 Listen now: bit.ly/FDATVandMET #LungCancer #NSCLC

After years of raising awareness, Dr. Bryant Lin was diagnosed with stage IV EGFR+ lung cancer. In the new #LungCancerConsidered episode, he talks with @stephenvliu.bsky.social about patient experience, treatment, and teaching cancer care. 🎧 Listen: bit.ly/LinTMLC

To all SITC members - election starts May 2 and I strongly support Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. One of the most capable and intelligent people I know - and a caring mentor and colleague. Vote Tina! www.sitcancer.org/membership/2...

To all SITC members - election starts May 2 and I strongly support Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. One of the most capable and intelligent people I know - and a caring mentor and colleague. Vote Tina! www.sitcancer.org/membership/2...

On the new episode of #LungCancerConsidered, we dive into how the microbiome impacts lung cancer & immunotherapy. @stephenvliu.bsky.social talks with Drs. Arielle Elkrief & Bertrand Routy about what we know and what we don’t. 🎧 Listen now: bit.ly/MI-NSCLC #LungCancer #Immunotherapy

🎙️ Don't miss this all-new episode of #LungCancerConsidered! Host @stephenvliu.bsky.social continues our #VirtualTumorBoard series with a complex Stage III ALK+ #NSCLC case. How should clinicians approach this patient? Listen now for expert insights! 🎧 bit.ly/VTBsIIIALK #ALKPositive #IASLC

Disclosure: For someone like me, who was dx w stage 4 #lungcancer in 2022 and have been cancer-free for 2 years, a cancer vaccine is one of the most promising ways to prevent cancer from coming back. Always a pleasure to learn from @stephenvliu.bsky.social. #lcsm #oncosky wtop.com/drugs-and-me...

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

Small cell in never smokers. On the rise for unknow reasons and a different biology. Having recently encountered my first patient who’s a never smoker(and no alcohol or recreational drugs), with extensive stage disease this insight is fascinating @stephenvliu.bsky.social #BTOG25

Great session on systemic therapy for SCLC by @stephenvliu.bsky.social at #BTOG23 ➡️ BiTE engages, ADCs and many other agents showing promise ➡️ Possible role for radioligands ➡️ New never smokers phenotype emerging ➡️ Many reasons to be hopeful! @drjnaidoo.bsky.social @tnewsomdavis.bsky.social

Although @stephenvliu.bsky.social is hard to follow, we’ve just had an absolute tour de force by @drjnaidoo.bsky.social at #BTOG25 on #SCLC ➡️ Discusses NRG005 and the better outcomes for patients reviving twice daily radiotherapy. ➡️ Continued evidence of a benefit from PCI in LS-SCLC

Packed house at #BTOG25’s SC lung cancer session Dr @stephenvliu.bsky.social talks of need to ID those that do/don’t derive benefit, find biomarkers, review optimal sequencing & better understand evolving biology of #SCLC. Describes SCLC in ppl w no/light smoking history. #LCSM @btog.bsky.social

Agree. A packed room for SCLC on the last day of a conference? Unheard of previously! Obviously all attending to listen to @annaminchom.bsky.social , @drjnaidoo.bsky.social ,& @stephenvliu.bsky.social! @btog.bsky.social #BTOG25

@stephenvliu.bsky.social: SCLC, ADCs ❇️ TROP2: has potential, respectable 40% ORR ❇️ SEZ6: impressive depth of response, but early days ❇️ B7-H3: most impressive efficacy, but ❗️toxicity - especially ILD But exciting developments: There is a New Hope in SCLC

Superstar #BTOG25 speakers, and the boss

Always an interesting podcast with @stephenvliu.bsky.social "Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance" via @iaslc.bsky.social https://buff.ly/3QuhOTA

The full agenda for the Texas Lung Cancer Conference is live! Join us April 10-12, 2025 at Austin City Limits for the IASLC-endorsed CME meeting covering all things lung cancer with an amazing faculty roster & agenda! Register now for #TexasLung25 & see you there! thetlcconference.com/agenda-2025/

This week, we highlighted exciting research from our GI and Lung oncology colleagues: Alison M Schram, Teresa Macarulla, Eileen O'Reilly, Benjamin A Weinberg, @stephenvliu.bsky.social, Tanios Bekaii-Saab, Kim A Reiss, Alexander Drilon, and others published in @nejm.org. Learn more: bit.ly/3WPoiQB.

Results from the phase II study of zenocutuzumab in #NRG1 fusion+ cancers now @nejm.org. RR 30% with DOR 11.1m, PFS 6.8m, favorable safety profile. NRG1+ lung cancers do not respond well to standard therapy. Zenocutuzumab now FDA approved for NSCLC, pancreatic cancer. www.nejm.org/doi/full/10....

🚨 Applications are now open for the JTO Reviewer Workshop! If you’re interested in enhancing your review skills and contributing to the field, apply by April 4. Don’t miss this opportunity to get involved! #JTO #ReviewerWorkshop #IASLC #LungCancer #Research Apply here: www.iaslc.org/reviewer-wor...

In Gran Canaria for #ITCD2025 with my dear friend @arselaprelaj.bsky.social

Register now to join my co-chair Dr. Tina Cascone & me on April 10-12, 2025 at Austin City Limits for #TexasLung25 - a 2d #CME conference with > 80 lung cancer experts discussing current standards of care. Something for everyone: oncologists, trainees, nurses, pharmacists! thetlcconference.com

Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months. www.jnj.com/media-center...

CHRYSALIS-2 Cohort A: amivantamab + lazertinib in #EGFR NSCLC after osimertinib and chemotherapy @jtoonline.bsky.social (n=162). BICR RR 35%, CBR 58%, DOR 8.3m, PFS 4.5m, OS 14.8m, and CNS efficacy noted. AEs included rash in 81% (G3 10%), paronychia in 52%. www.jto.org/article/S155...

In the latest episode of the @iaslc.bsky.social podcast, Lung Cancer Considered, I discussed the FDA approved CheckMate 77T regimen of perioperative nivolumab + chemotherapy for resectable NSCLC with Drs. Tina Cascone & Shun Lu. Great insights here - have a listen! www.iaslc.org/iaslc-news/l...

Will the future of lung cancer biomarkers be based on deep learning and #AI? Deep learning model predicts response to immunotherapy in NSCLC from one histology slide and performed better than TMB, PD-L1. Report now in JAMA Oncology. jamanetwork.com/journals/jam...

Perioperative osimertinib for resectable #EGFR NSCLC in the single institution NORA trial @jtoonline.bsky.social. After 56d of neoadjuvant osimertinib, RR 44%, MPR 24%, pCR rate 0%. 3y adjuvant osimertinib given; mDFS not yet reached after 31m. www.jto.org/article/S155...

One of the forgotten costs of cancer therapy is time spent in the clinic. Report on time toxicity in JCO Oncology Practice on pts with lung cancer showed 22% of days alive had in person visits: 24% with chemotherapy, 21% for immunotherapy, 16% for targeted therapy. #LCSM ascopubs.org/doi/10.1200/...

Able to connect virtually with friends in China including Drs. Yilong Wu, Ying Cheng, Yue Yin Pan, and Chunxia Su to discuss the future of treating lung cancer, balancing efficacy and safety, and accelerating advances for all of our patients.

Results from J-TAIL-2 trial @JTOonline. Prospective 1L carboplatin, etoposide, & atezolizumab for #SCLC. 12m OS rate 63.7%, mOS 16.5m. In trial-like population (by eligibility), 12m OS 77.5%, mOS 19.1m. In ineligible population, 12m OS 58.5%, mOS 15.5m. www.jtocrr.org/article/S266...

FDA approves ensartinib for #ALK NSCLC based on phase III eXALT3 trial that compared 1L ensartinib & crizotinib. PFS favored ensartinib (25.8m vs 12.7m, HR 0.56), no OS difference. Active drug but unlikely to impact care for most, unless cost is much less. #OncSky #LCSM www.fda.gov/drugs/resour...

Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials @stephenvliu.bsky.social @mskcancercenter.bsky.social @nufeinbergmed.bsky.social @harvardmed.bsky.social @ucsdhealth.bsky.social #lcsm www.onclive.com/view/taletre...